Fig. 2 | Scientific Reports

Fig. 2

From: Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma

Fig. 2

Effects of QR-KLU on the toxicity to normal red blood cells and the proliferation activity of liver cancer cells (n = 6). (A) Representative hemolysis graphs of various concentrations of KLU, QR, and QR-KLU co-incubated with rabbit red blood cells. (B) CCK8 assay evaluating the effects of DOX, QR, KLU, and QR-KLU on the proliferation activity of Hepa1–6 cells under normoxic and hypoxic conditions. Hypoxic condition was created by adding 100 µM cobalt dichloride. CCK8 cell counting kit-8, DOX doxorubicin, QR-KLU peptide (QR)–drug (KLU) conjugate.

Back to article page